Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...

Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial ...

Pheno Therapeutics Ltd. has received clinical trial authorization (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its lead candidate, PTD-802. The program will ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Small molecule therapeutic designed for treatment of neurological diseases such as multiple sclerosis EDINBURGH, Scotland, January 14, 2025--(BUSINESS WIRE)--Pheno Therapeutics Limited., a ...

UK MHRA grants CTA for first-in-human trial of a selective GPR17 antagonist Small molecule therapeutic designed for treatment of neurological diseases such as multiple sclerosis Pheno Therapeutics ...